Expression level of E‑, N‑ and P‑cadherin proteins in endometrial cancer

Lewczuk,Łukasz; Pryczynicz,Anna; Guzińska‑Ustymowicz,Katarzyna

doi:10.3892/ol.2021.12522

Expression level of E‑, N‑ and P‑cadherin proteins in endometrial cancer

Authors:
- Łukasz Lewczuk
- Anna Pryczynicz
- Katarzyna Guzińska‑Ustymowicz
View Affiliations

Affiliations: Department of General Pathomorphology, Medical University of Bialystok, 15‑269 Bialystok, Poland
Published online on: February 4, 2021 https://doi.org/10.3892/ol.2021.12522
Article Number: 261
Copyright: © Lewczuk et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to examine the protein expression levels of E‑, N‑ and P‑cadherin, which are involved in the proliferation of neoplastic cells, in cancer tissue from patients with endometrial cancer. Furthermore, the present study aimed to investigate the effect of these proteins on clinicopathological parameters. Immunohistochemistry was performed to detect the protein expression levels of the aforementioned cadherins in 38 primary endometrial tumors, 20 metastatic tumors (nine metastases to the lymph nodes and 11 distant metastases) and five cases of atypical hyperplasia as the control group. It was found that the E‑, N‑ and P‑cadherin proteins in hyperplastic endometrial lesions with atypia were weakly expressed in the cytoplasm, while the expression levels of E‑, N‑ and P‑cadherin proteins, in endometrial cancer tissue, were located in the membrane and/or in the cytoplasm, and was found to be unevenly distributed. Furthermore, increased expressed level of the three cadherin proteins was observed at the tumor front, as opposed to in the main mass, of endometrial cancer tumor. It was demonstrated that membrane expression levels of the 3 cadherin proteins were lower in metastatic cancer cells compared with that in the primary tumor cells. In addition, a significantly higher cytoplasmic expression level of E‑cadherin and increased membranous and cytoplasmic expression of P‑cadherin, were associated with high‑grade tumor budding. Furthermore, a higher percentage of P‑cadherin membrane expression level was associated with poorly differentiated cancer cell types. The present results suggested that the increased membrane expression level of E‑cadherin was associated with the presence of local lymph node involvement.

View Figures

View References

1	Lortet-Tieulent J, Ferlay J, Bray F and Jemal A: International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 110:354–361. 2018. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 v1.0. IARC CancerBase. No. 11. Lyon: 2013
3	Prat J, Franceschi S, Denny L, Lazcano Ponce E, Stewart BW and Wild CP: Endometrial cancer. World Cancer Report 2014. Steward BW and Wild CP: International Agency for Research on Cancer; Lyon: pp. 465–481. 2014
4	Wallez Y and Huber P: Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. Biochim Biophys Acta. 1778:794–809. 2008. View Article : Google Scholar : PubMed/NCBI
5	Halbleib JM and Nelson WJ: Cadherins in development: Cell adhesion, sorting, and tissue morphogenesis. Genes Dev. 20:3199–3214. 2006. View Article : Google Scholar : PubMed/NCBI
6	van Roy F: Beyond E-cadherin: Roles of other cadherin superfamily members in cancer. Nat Rev Cancer. 14:121–134. 2014. View Article : Google Scholar : PubMed/NCBI
7	Pal M, Bhattacharya S, Kalyan G and Hazra S: Cadherin profiling for therapeutic interventions in epithelial mesenchymal transition (EMT) and tumorigenesis. Exp Cell Res. 368:137–146. 2018. View Article : Google Scholar : PubMed/NCBI
8	Son H and Moon A: Epithelial-mesenchymal transition and cell invasion. Toxicol Res. 26:245–252. 2010. View Article : Google Scholar : PubMed/NCBI
9	Oda H, Tsukita S and Takeichi M: Dynamic behavior of the cadherin-based cell-cell adhesion system during Drosophila gastrulation. Dev Biol. 203:435–450. 1998. View Article : Google Scholar : PubMed/NCBI
10	Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, Höfler H and Becker KF: Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol. 161:1881–1891. 2002. View Article : Google Scholar : PubMed/NCBI
11	Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y and Johnson KR: Cadherin switching. J Cell Sci. 121:727–735. 2008. View Article : Google Scholar : PubMed/NCBI
12	Gravdal K, Halvorsen OJ, Haukaas SA and Akslen LA: A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res. 13:7003–7011. 2007. View Article : Google Scholar : PubMed/NCBI
13	Nieman MT, Prudoff RS, Johnson KR and Wheelock MJ: N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol. 147:631–644. 1999. View Article : Google Scholar : PubMed/NCBI
14	Li G, Satyamoorthy K and Herlyn M: N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 61:3819–3825. 2001.PubMed/NCBI
15	Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, Katagiri T and Nakamura Y: Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Res. 65:3092–3099. 2005. View Article : Google Scholar : PubMed/NCBI
16	Shimoyama Y and Hirohashi S: Expression of E- and P-cadherin in gastric carcinomas. Cancer Res. 51:2185–2192. 1991.PubMed/NCBI
17	Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
18	Ahmed AR and Muhammad EM: E-cadherin and CD10 expression in atypical hyperplastic and malignant endometrial lesions. J Egypt Natl Canc Inst. 26:211–217. 2014. View Article : Google Scholar : PubMed/NCBI
19	Carico E, Atlante M, Giarnieri E, Raffa S, Bucci B, Giovagnoli MR and Vecchione A: E-cadherin and alpha-catenin expression in normal, hyperplastic and neoplastic endometrium. Anticancer Res. 30:4993–4997. 2010.PubMed/NCBI
20	Xie X, Zheng X, Wang J and Chen L: Clinical significance of Twist, E-cadherin, and N-cadherin protein expression in endometrioid adenocarcinoma. J Cancer Res Ther. 13:817–822. 2017. View Article : Google Scholar : PubMed/NCBI
21	Nguyen HP, Xiao L, Deane JA, Tan KS, Cousins FL, Masuda H, Sprung CN, Rosamilia A and Gargett CE: N-cadherin identifies human endometrial epithelial progenitor cells by in vitro stem cell assays. Hum Reprod. 32:2254–2268. 2017. View Article : Google Scholar : PubMed/NCBI
22	Veatch AL, Carson LF and Ramakrishnan S: Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer. 58:393–399. 1994. View Article : Google Scholar : PubMed/NCBI
23	Risinger JI, Berchuck A, Kohler MF and Boyd J: Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet. 7:98–102. 1994. View Article : Google Scholar : PubMed/NCBI
24	Moreno-Bueno G, Hardisson D, Sarrió D, Sánchez C, Cassia R, Prat J, Herman JG, Esteller M, Matías-Guiu X and Palacios J: Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol. 199:471–478. 2003. View Article : Google Scholar : PubMed/NCBI
25	Koyuncuoglu M, Okyay E, Saatli B, Olgan S, Akin M and Saygili U: Tumor budding and E-cadherin expression in endometrial carcinoma: Are they prognostic factors in endometrial cancer? Gynecol Oncol. 125:208–213. 2012. View Article : Google Scholar : PubMed/NCBI
26	Lee SJ, Choi SY, Kim WJ, Ji M, Lee TG, Son BR, Yoon SM, Sung R, Lee EJ, Youn SJ and Park SM: Combined aberrant expression of E-cadherin and S100A4, but not β-catenin is associated with disease-free survival and overall survival in colorectal cancer patients. Diagn Pathol. 8:992013. View Article : Google Scholar : PubMed/NCBI
27	Karamitopoulou E, Zlobec I, Panayiotides I, Patsouris ES, Peros G, Rallis G, Lapas C, Karakitsos P, Terracciano LM and Lugli A: Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer. Hum Pathol. 42:1888–1896. 2011. View Article : Google Scholar : PubMed/NCBI
28	Zheng X, Du XL and Jiang T: Prognostic significance of reduced immunohistochemical expression of E-cadherin in endometrial cancer-results of a meta-analysis. Int J Clin Exp Med. 8:18689–18696. 2015.PubMed/NCBI
29	Piura B, Rabinovich A, Aizenberg N and Wolfson M: Cadherins in malignancies of the female genital tract. Harefuah. 144:261–265, 303, 302. 2005.(In Hebrew). PubMed/NCBI
30	Stefansson IM, Salvesen HB and Akslen LA: Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol. 22:1242–1252. 2004. View Article : Google Scholar : PubMed/NCBI
31	Singh M, Darcy KM, Brady WE, Clubwala R, Weber Z, Rittenbach JV, Akalin A, Whitney CW, Zaino R, Ramirez NC and Leslie KK: Cadherins, catenins and cell cycle regulators: Impact on survival in a gynecologic oncology group phase II endometrial cancer trial. Gynecol Oncol. 123:320–328. 2011. View Article : Google Scholar : PubMed/NCBI